WOODCLIFF LAKE, N.J., June 23, 2014 /PRNewswire/ -- An analysis of data from the 2012 U.S. National Health and Wellness Survey showed that the majority of those affected by obesity are not taking steps to lose weight (58.4%). The analysis of more than 71,157 respondents, including approximately 23,000 adults with obesity, was conducted by Eisai Inc. and Kantar Health and results were highlighted as part of an official news conference at the 16th International Congress of Endocrinology and The Endocrine Society's 96th Annual Meeting and Expo (ICE/ENDO 2014) in Chicago, Ill.
The survey also revealed that among those who did take measures to lose weight, prescription weight loss medications and surgical procedures yielded greater satisfaction (39.3%), measured by the percentage of respondents who reported they were extremely or very satisfied with treatment, versus self-modification methods alone such as diet, exercise and weight management programs (20.2%).
"These findings show that diet and exercise alone may not work for a lot of people and identifying methods that lead to greater satisfaction may help get people on track for achieving and maintaining long-term weight loss," said Z. Jason Wang, PhD, the study's principal investigator and Director of Health Economics and Outcomes Research at Eisai Inc.
"Eisai is committed to advancing knowledge about the treatment of obesity, a chronic, progressive disease that has serious health consequences," added Gary Palmer, Chief Medical Officer and Vice President, Medical Affairs at Eisai Inc. "The results of the survey suggest the need for more education on the health effects of obesity and available treatment options and underscore the importance of physicians needing to have a dialogue with patients to determine the most appropriate weight loss plan for them."
About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.
Logo - http://photos.prnewswire.com/prnh/20120413/MM87168LOGO
SOURCE Eisai Inc.